SAN DIEGO, CA--(Marketwired - Jun 28, 2016) - SpectraScience, Inc. (OTCQB: SCIE), a medical device company utilizing light technologies to detect and diagnose cancers, announced today that they have expanded their licensing agreement with Duke University to include an additional patent. This patent is an enhancement to the current license portfolio of intellectual property around systems and methods for the use of Angle-Resolved Low Coherence Interferometry in the diagnosis of certain cancers.
"We continue to look for opportunities to improve the breadth and the depth of our Intellectual Property portfolio," said Michael Oliver, President and Chief Executive Officer of SpectraScience, Inc. "The patent we have added to our license with Duke University will help us ensure freedom to operate within indications of interest. With the potential to develop a product for light-based diagnosis of Barrett's Esophagus, a precursor to esophageal cancer, we will continue to broaden our product offerings. Our goal is to be the premier company using light to provide in vivo diagnosis of cancer."
About SpectraScience, Inc.:
SpectraScience is a San Diego based medical device company that designs, develops, manufactures and markets spectrophotometry systems capable of determining whether tissue is normal, pre-cancerous or cancerous without physically removing tissue from the body. Protected by more than 30 patents in 28 countries, covering fundamental elements of the technology, the WavSTAT Optical Biopsy System uses light to optically scan tissue and provide the physician with an immediate analysis. With FDA approval for sale in the U.S. and the CE Mark for the European Union, the WavSTAT System is the first commercially available product that incorporates this innovative patent protected technology for clinical use.
For more information:
Visit our web site www.spectrascience.com
Forward-Looking Statement for SpectraScience, Inc.
This news release contains forward-looking statements that involve risks and uncertainties that may cause SpectraScience's actual results to differ materially from results discussed in forward-looking statements. Readers are urged to carefully review and consider the various disclosures made by SpectraScience in this news release, its most recent Form 10-K and in SpectraScience's other reports filed with the Securities and Exchange Commission ("SEC") that attempt to advise interested parties of the risks and factors that may affect SpectraScience's business. These forward-looking statements are qualified in their entirety by the cautions and risk factors filed by SpectraScience in its annual report on Form 10-K and other documents.